Rayence Co. Ltd - Asset Resilience Ratio
Rayence Co. Ltd (228850) has an Asset Resilience Ratio of 38.97% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 228850 current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Rayence Co. Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Rayence Co. Ltd asset portfolio.
Liquid Assets Composition Over Time
This chart breaks down Rayence Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read total liabilities of Rayence Co. Ltd for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩106.00 Billion | 38.97% |
| Total Liquid Assets | ₩106.00 Billion | 38.97% |
Asset Resilience Insights
- Very High Liquidity: Rayence Co. Ltd maintains exceptional liquid asset reserves at 38.97% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Rayence Co. Ltd Industry Peers by Asset Resilience Ratio
Compare Rayence Co. Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Medtronic plc
SA:MDTC34 |
Medical Devices | 7.82% |
|
Demant A/S
CO:DEMANT |
Medical Devices | -2.59% |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223 |
Medical Devices | 0.84% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 34.37% |
|
Sinocare Inc
SHE:300298 |
Medical Devices | 3.53% |
|
Emvision Medical Devices Ltd
AU:EMV |
Medical Devices | 0.06% |
|
Theradiag SA
PA:ALTHE |
Medical Devices | 15.59% |
|
Biosynex
PA:ALBIO |
Medical Devices | 3.35% |
Annual Asset Resilience Ratio for Rayence Co. Ltd (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Rayence Co. Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 39.81% | ₩104.00 Billion ≈ $70.48 Million |
₩261.22 Billion ≈ $177.02 Million |
-15.98pp |
| 2024-12-31 | 55.79% | ₩150.21 Billion ≈ $101.79 Million |
₩269.22 Billion ≈ $182.44 Million |
+2.22pp |
| 2023-12-31 | 53.57% | ₩148.65 Billion ≈ $100.74 Million |
₩277.49 Billion ≈ $188.05 Million |
+3.67pp |
| 2022-12-31 | 49.90% | ₩130.73 Billion ≈ $88.59 Million |
₩262.00 Billion ≈ $177.55 Million |
+0.96pp |
| 2021-12-31 | 48.94% | ₩118.33 Billion ≈ $80.19 Million |
₩241.80 Billion ≈ $163.86 Million |
+3.79pp |
| 2020-12-31 | 45.15% | ₩101.45 Billion ≈ $68.75 Million |
₩224.72 Billion ≈ $152.29 Million |
+6.72pp |
| 2019-12-31 | 38.43% | ₩89.18 Billion ≈ $60.43 Million |
₩232.07 Billion ≈ $157.27 Million |
-4.47pp |
| 2018-12-31 | 42.89% | ₩86.27 Billion ≈ $58.46 Million |
₩201.13 Billion ≈ $136.30 Million |
-3.03pp |
| 2017-12-31 | 45.92% | ₩90.21 Billion ≈ $61.13 Million |
₩196.45 Billion ≈ $133.13 Million |
+1.21pp |
| 2016-12-31 | 44.71% | ₩85.12 Billion ≈ $57.68 Million |
₩190.36 Billion ≈ $129.00 Million |
-- |
About Rayence Co. Ltd
Rayence Co., Ltd., together with its subsidiaries, engages in the development, manufacture, and sale of digital X-ray detector products for dental, medical, veterinary, and industrial sectors in South Korea, the United States, Mexico, China, and internationally. The company offers TFT/CMOS X-ray detectors for general radiography, C-arm/RF, mammography, and radiotherapy; and CMOS/Super IGZO TFT/a-… Read more